EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSDLAG00005006275
Gene Symbol: DHCR24
1 Cross references
209 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase B

Ensembl ID : ENSDLAG00005021232
Gene Symbol: HMGCRB
1 Cross references
206 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSDLAG00005021439
Gene Symbol: NT5E
1 Cross references
190 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSDLAG00005000098
Gene Symbol: NT5E
1 Cross references
194 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 1a B

Ensembl ID : ENSDLAG00005030486
Gene Symbol: HTR1AB
1 Cross references
138 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSDLAG00005012512
Gene Symbol: HTR2B
1 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSDLAG00005000141
Gene Symbol: HTR2CL1
1 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSDLAG00005011430
Gene Symbol: HTR5AB
2 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSDLAG00005000083
Gene Symbol: HTR1B
1 Cross references
183 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSDLAG00005021540
Gene Symbol: HTR1B
1 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSDLAG00005004609
Gene Symbol: HTR1E
1 Cross references
150 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSDLAG00005033564
Gene Symbol: HTR1F
1 Cross references
143 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).